Application of extracorporeal therapies in critically ill COVID-19 patients
- Author:
ZHOU ZHIFENG
1
;
KUANG HUANG
;
MA YUEXIAN
;
ZHANG LING
Author Information
1. Department of Nephrology,Kidney Research Institute,West China Hospital,Sichuan University,Chengdu 610041,China
- Keywords:
Coronavirus disease 2019 (COVID-19);
Critical illness;
Cytokine release syndrome (CRS);
Acute kidney injury (AKI);
Extracorporeal therapy
- From:
Journal of Zhejiang University. Science. B
2021;22(9):701-717
- CountryChina
- Language:Chinese
-
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic is a major public health event caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread widely all over the world. A high proportion of patients become severely or critically ill, and suffer high mortality due to respiratory failure and multiple organ dysfunction. Therefore, provid-ing timely and effective treatment for critically ill patients is essential to reduce overall mortality. Convalescent plasma therapy and pharmacological treatments, such as aerosol inhalation of interferon-α (IFN-α), corticosteroids, and tocilizumab, have all been applied in clinical practice;however, their effects remain controversial. Recent studies have shown that extracorporeal therapies might have a potential role in treating critically ill COVID-19 patients. In this review, we examine the application of continuous renal replacement therapy (CRRT), therapeutic plasma exchange (TPE), hemoadsorption (HA), extracorporeal membrane oxygenation (ECMO), and extracorporeal carbon dioxide removal (ECCO2R) in critically ill COVID-19 patients to provide support for the further diagnosis and treatment of COVID-19.
